Aaron Vickers is an Independent Correspondent at NHL.com. He specializes in competitive sports, with a focus on team sports and various sports disciplines. Aaron's work has been featured in the National Hockey League (NHL), Future Considerations Hockey Inc, NewsBreak, and the Cureus Journal of Medical Science.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Aaron Vickers' coverage is heavily focused on sports, particularly hockey and the NHL. His work emphasizes event coverage and evolving stories within the world of professional hockey.
For effective outreach, consider providing insider insights for ongoing or upcoming events in the NHL, especially those involving teams like Flames, Canucks, Wild, Kraken, Devils and Stars. Additionally, if there are any major announcements or press releases related to these teams or significant players in the league, they may be of interest to him.
Given his focus on specific games and player performances within the NHL context (such as highlight-worthy goals or exceptional saves), offering exclusive interviews with players or coaches could also capture Aaron's attention.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Aaron Vickers
10-year Predators veteran remains 'one of those guys you want on your team'
By: Aaron Vickers
20-year-old Ducks center could 'be a top player for a long time' on international stage
Ducks 20-årige center kan bli ”en toppspelare under lång tid” på den internationella scenen
By: Aakash Desai, Yanis Boumber, Drexell H. Boggs, Aaron Vickers, Tingting Zhang, Amr Ismail
Graft rejection is the major challenge that solid organ transplant recipients face. As a consequence, lung cancer patients of this population have been consistently excluded from clinical trials involving the use of immunotherapy agents due to the increased risk of graft rejection. Tarlatamab is a novel bi-specific T-cell recruiter monoclonal antibody targeting delta-like ligand 3 (DLL3) on cancer cells and CD3 on T-cells; hence, it is theoretically much safer than other checkpoint inhibitor immunotherapy agents that boost T-cells non-specifically. Tarlatamab received Food and Drug Administration (FDA) approval in 2024 for the treatment of adults with extensive-stage small-cell lung cancer (ES-SCLC) that has progressed on or after platinum-based chemotherapy. Here, we report safe treatment of an extensive-stage small-cell lung cancer patient with an orthotopic heart transplant with tarlatamab. The patient received four doses between April and June 2025 without evidence of graft rejection or dysfunction. As of August 2025, the patient continues treatment without any adverse events.
Kraken's Annborn, Rangers' Eriksen putting up big numbers overseas By Aaron Vickers NHL.com International Editorial Manager
By: Aaron Vickers
Eklund of Islanders, Frondell of Blackhawks performing well overseas By Aaron Vickers NHL.com International Editorial Manager
By: Aaron Vickers
2025 1st-round picks Frondell, Eklund among those to compete in Minnesota By Aaron Vickers NHL.com International Editorial Manager
By: Aaron Vickers
Berglund, Harenstam, Cihar among those with strong showing at tournament By Aaron Vickers NHL.com International Editorial Manager
By: Aaron Vickers
Vilmanis, Spacek, Gajan set to compete at Olympics By Aaron Vickers NHL.com International Editorial Manager
By: Aaron Vickers
Frondell, Keskinen, Farhammar close out regular seasons with big numbers By Aaron Vickers NHL.com International Editorial Manager
